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Hydrogen sulﬁde (H2S) is the most recent endogenous gasotransmitter that has been reported to serve
many physiological and pathological functions in different tissues. Studies over the past decade have
revealed that H2S can be synthesized through numerous pathways and its bioavailability regulated
through its conversion into different biochemical forms. H2S exerts its biological effects in various man-
ners including redox regulation of protein and small molecular weight thiols, polysulﬁdes, thiosulfate/
sulﬁte, iron-sulfur cluster proteins, and anti-oxidant properties that affect multiple cellular and molecu-
lar responses. However, precise measurement of H2S bioavailability and its associated biochemical and
pathophysiological roles remains less well understood. In this review, we discuss recent understanding
of H2S chemical biology, its relationship to tissue pathophysiological responses and possible therapeutic
uses.
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Hydrogen sulﬁde (H2S) has emerged as an important gaseous
signaling molecule playing numerous roles in health and disease,
along with CO and NO [1,2]. It acts as a relaxant of smooth muscle
and thus a vasodilator, a regulator of cardiac function and N-
methyl D-aspartate (NMDA) receptor in the brain, and cytoprotec-
tant and mediator for cardiovascular therapeutic approaches [3–8].
Understanding precise pathophysiological signaling mechanisms
and the metabolism of H2S is a topic of active research. Unraveling
H2S interactions within different tissues, with other biochemical
molecules and various signaling mediators is becoming ever more
complex. Thus, in this rapidly growing ﬁeld it is important to
appreciate key ﬁndings and their potential implications regarding
H2S chemical biology that are now known, as well as to identify
critical areas for further understanding and clariﬁcation. In this re-
view, we address numerous salient issues regarding biochemical
synthesis and metabolism of H2S, measurement techniques used
to detect levels of H2S both in vitro and in vivo, biological functions
regulated by H2S and the potential of therapeutic approaches
employing H2S based therapies for various clinical applications.H2S biosynthesis: enzymatic and non-enzymatic
The production of H2S can occur via two pathways – enzymatic
and non-enzymatic. Enzymatic synthesis of H2S occurs through
three enzymes that are cystathionine gamma-lyase (CGL also
abbreviated as CSE), cystathionine beta-synthase (CBS) and 3-mer-
captopyruvate sulfurtransferase (3-MST). These enzymes have
been reported to be organ-speciﬁc depending on the type of en-
zyme. CBS is predominantly found in the brain, nervous system,
and liver [4], while CSE is mostly found in the vasculature and liver,
and 3-MST can be found in the brain and vasculature [9]. However,
all three enzymes are distributed across many tissues and are often
jointly present such as CBS and CSE being most prominently found
in the liver and kidney [9]. Importantly, while CSE and CBS are
hemeproteins primarily located in the cytosol, 3-MST is a zinc-
dependent protein found in both the mitochondria and cytosol.
Cystathionine is a critical intermediate metabolite involved in
many sulfur-containing amino acids, formed by CBS through con-
densation of homocysteine along with serine. CSE is also involved
in a reaction that converts L-cystathionine and cysteine to form L-
cysteine and a-ketoglutarate (a-KG). CSE and CBS ultimately pro-
duce H2S through a reaction involving the generation of L-cysteine,
pyruvate, and ammonia. Likewise, 3-MST produces H2S through a
reaction involving the generation of pyruvate from 3-mercaptopy-
ruvate (3-MP). It has recently been shown that 3-MST might also
cleave mercaptopyruvate to form pyruvate and H2S, or catalyze
the transsulfuration of a thiol to a persulﬁde, which can subse-
quently join a second thiol to form a disulﬁde and release H2S
[10]. 3-MP substrate is provided through the metabolism of cys-
teine and a-KG by cysteine aminotransferase (CAT). Fig. 1 illus-
trates how these enzymes coordinately regulate transsulfurationactivity controlling physiological H2S levels in a complex and over-
lapping manner.
Apart from enzymatic synthesis pathways, endogenous produc-
tion of H2S can also occur through other non-enzymatic processes
that are less well understood. Non-enzymatic production of H2S
occurs through glucose, glutathione, inorganic and organic polysul-
ﬁdes (present in garlic) and elemental sulfur. H2S can be generated
from glucose either via glycolysis or from phosphogluconate via
NADPH oxidase. Glucose reacts with methionine, homocysteine
or cysteine to produce gaseous sulfur compounds – methanethiol
and hydrogen sulﬁde. H2S is also produced through direct reduc-
tion of glutathione and elemental sulfur. Reduction of elemental
sulfur to H2S is mediated through reducing equivalents of the glu-
cose oxidation pathway such as NADH, or NADPH [11]. H2S forma-
tion from thiosulfate results from a reductive reaction involving
pyruvate, which acts as a hydrogen donor. Thiosulfate is an inter-
mediate of sulfur metabolism from cysteine and a metabolite of
H2S that can also lead to the production of H2S [12–14]. Though
the involvement of mitochondria in oxidizing sulﬁde has been well
known [15], the speciﬁc afﬁnity of the enzyme 3-MST to thiosul-
fate and in its production has been recently reported [16,17]. Fur-
ther, rhodanese is involved in metabolizing thiosulfate into H2S
and sulﬁte [13]. Fig. 1 summarizes various enzymatic and non-
enzymatic H2S synthesis pathways that have been described.Different biochemical forms of sulﬁde
Apart from its free state, H2S can react with different biochem-
ical molecules establishing different bioavailable pools including
stable, acid-labile and bound sulﬁde forms (Fig. 2). In the stable
pool, sulfur atoms are not readily reactive or liberated upon chem-
ical treatment with acid or dithiothreitol [14]. These compounds
exist in a reduced divalent form such as H2S or oxidized hexavalent
form such as sulfate anion. Sulﬁde can also be categorized based on
the form in which they are stored in a biological system such as
free sulﬁdes or in bound forms such as acid-labile forms and bound
sulfane sulfur [18]. Free or unbound sulﬁde exists as S2, HS or
H2S, where its acidic dissociation constants (pKa) range between
>12 and 7.0, respectively (Fig. 2). Acid-labile sulﬁde is mainly in
the form of iron–sulfur (Fe–S) complexes and persulﬁdes, which
play a critical role in redox reactions in cytoplasm and mitochon-
dria. The critical pH below which H2S is released from acid-labile
sulfur like Fe–S is 5.4 [19]. Conversely, bound sulfane sulfur exists
as a compound containing sulfur-bonded sulfur [20]. This includes
compounds like polysulﬁdes, thiosulfate, polythionates, thiosulfo-
nates bisorganyl-polysulfanes or monoarylthiosulfonates and ele-
mental sulfur. Bound-sulfane sulfur compounds such as
polysulﬁdes release H2S under reducing conditions suggesting that
cellular redox state is important for regulating its bioavailability
[21]. Moreover, free H2S can be incorporated into proteins as
bound sulfane sulfur, where its divalent sulfur form binds only to
the elemental sulfur, persulﬁdes and polysulﬁdes [22]. These
various biochemical forms represent complex and diverse ways
in which H2S bioavailability can be maintained. However, the
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physiological conditions in which they are biochemically con-
verted remains poorly understood.
H2S interacts with membrane and cytosolic proteins to produce
reactive and unstable persulﬁdes. These persulﬁdes can be further
converted to other biochemical forms including thiocysteine, thi-Fig. 1. Enzymatic and non-enzymatic synthesis of H2S and its metabolism. Enzymatic sy
synthase (CBS), Cystathionine c-lyase (CGL or CSE) and 3-mercaptopyruvate sulfurtr
glutathione and polysulﬁdes. H2S further metabolized into thiocyanate, methanethio
thiosulfate reductase (TSR) enzymes respectively. Thiosulfate can oxidize to sulﬁte throu
hemoglobin to form sulfhemoglobin and with proteins in the tissues in the form of bouotaurine, protein–SSH, thiocystine, mercaptopyruvate and others.
Sulﬁde donors may impart structural changes in proteins through
persulﬁde related sulfuration and sulfhydration reactions of pro-
teins. Oxidized GSSG can non-enzymatically react with H2S to form
glutathione persulﬁde [23]. Likewise, reduced GSH also plays a cat-
alytic role in elemental sulfur activation. Thus, numerous sulﬁdenthesis of H2S involves three enzymes in the mammalian systems, Cystathionine b-
ansferase (MST) to form H2S. Non-enzymatic synthesis occurs through glucose,
l and thiosulfate catalyzed by rhodanese, bisulﬁde methyltransferase (BMT) and
gh thiosulfate sulfurtransferase (TSST) and subsequently to sulfate. H2S reacts with
nd sulfur pool.
Fig. 2. Storage and release of H2S and factors involved. H2S can be interconverted between gaseous and other complex storage compounds involving various factors such as
pH, oxidation, reduction, hydrogenation, and alkalization, microorganisms like sulfate reducing bacteria (SRB), apart from enzymatic catalyses through CSE, CBS, 3MST, sulﬁte
reductase a-sub unit (CysJ), anaerobic sulﬁde reductase A (AsrA).
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chemical interactions with other molecular targets. These complex
interactions of sulﬁde pose challenging obstacles in determining
important biochemical forms that are present and active in biolog-
ical systems. However, future systematic experimental approaches
discretely aimed at understanding these complex sulﬁde variants
should provide signiﬁcant insight into speciﬁc roles of these
molecules.
Detection methods for H2S
Recent studies show that H2S plays physiological, pathological
and toxicological roles directly related to its bioavailable levels
in vitro and in vivo. Though physiologically the role of H2S seems
to be protective in nature, there is abundant evidence where seem-
ingly slight elevations in blood H2S levels mediate toxic effects. As
such, there is a continued interest in the research community to
understand the pathophysiological roles of H2S in relation to its
biological concentration [4,24–27]. The protective versus adverse
effects of H2S have been one of the most contentious, with conﬂict-
ing arguments for both effects being reported in the literature [28–
30]. Importantly, a similar historical research path was observed
with the study of NO having a dichotomous role as a cytoprotec-
tant and cytotoxicant. Thus, it is imperative that accurate measure-
ment of H2S in its free and various biochemical forms is
accomplished within biological systems to advance the under-
standing of this important molecule in pathophysiological settings.
The detection of sulﬁde and its pools has gained signiﬁcant
attention from analytical and biological communities. Thedetection methods for sulﬁde have evolved from simple colorimet-
ric assays to the more recently used techniques such as high pres-
sure liquid chromatography (HPLC), gas chromatography (GC),
mass spectrometry (MS), and polarographic, electrochemical and
chemiluminescent detection that are highly speciﬁc and sensitive
with much lower detection limits. However, each technique has
certain advantages and limitations that require careful consider-
ation before attempting to measure bioavailable sulﬁde and its var-
ious forms. Below we discuss several factors inﬂuencing detection
of sulﬁde in its various forms along with speciﬁc detection tech-
niques and their associated strengths and weaknesses.
Factors affecting H2S stability
pH is one of the key determining factors of H2S stability due to
its distinct acidic disassociation constants and ability to interact
with metals. As mentioned previously, sulﬁde may exist as differ-
ent biochemical species (acid labile forms) depending on the sur-
rounding pH conditions. The properties of sulﬁde distribution
and oxidation vary under different pH and temperature conditions
[31,32]. At physiological pH (7.4) and 37 C, 20% of sulﬁde exists
as H2S gas, while at pH 7.4 and 25 C 40% of sulﬁde exists as H2S
gas. At alkaline pH (e.g. 9.5), sulﬁde predominantly exists as HS
anion [33]. The reactivity of dissociated HS is high, as it is more
readily oxidized than H2S. In vivo free bioavailable sulﬁde primarily
exists in two forms as H2S gas and its highly reactive anion, HS
[15], thus deviations in pH from the physiological range can liber-
ate bound sulﬁde pools contributing to what would be detected as
free H2S/HS concentrations in biological specimens. The rate of
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maximum at pH 8; whereas, reactivity rates are decreased at both
low and high pHs reaching a nadir at pH 9 that gradually increases
as the pH range increases to 11 [31]. These examples illustrate the
importance of pH as a regulatory factor of sulﬁde chemical reac-
tions that clearly inﬂuence its measurement.
Another regulating factor that inﬂuences H2S stability is oxy-
gen (O2). From previous studies in non-biological [31,34] and bio-
logical samples [35], it has been shown that oxygen inﬂuences
the production and availability of sulﬁde. Olson et al. have shown
in lamprey aortae and rat and bovine arteries that H2S production
is increased in hypoxic conditions and inhibited upon subjecting
it to O2 [35]. Our group has further demonstrated that oxygen
concentration and pH affects sulﬁde stability and derivatization
within biological samples [36,37]. We found that at a pH of 9.5
at 21% oxygen the stability of sulﬁde was only 70%, improving
to 80% at 10% O2, and greater than 90% stability at 1% O2. To-
gether, these ﬁndings highlight that the stability and detection
of sulﬁde is critically affected by pH and oxygen tension and its
measurement would be most reliable with thoroughly deoxygen-
ated, pH-optimized reagents used under atmospherically con-
trolled conditions.
Speciﬁc measurement methods
Current literature reports several measurement techniques for
H2S from the basic to more analytically complex such as spectro-
photometry, chromatography, ion-selective electrode and nano-
particles that detect forms of sulﬁde from different non-
biological and biological sources like sewage, marine water, urine,
feces, blood, serum, tissues, and breath [14,38]. Continuous reﬁne-
ment of these techniques has improved detection speciﬁcity and
lowered threshold limitations. However, there are several techni-
cal, practical and biological uncertainties with several of these
measurement techniques.
The zinc trap/methylene blue and spectrophotometric assays
The colorimetric detection of the end product methylene blue
(MB) often referred to as the ‘zinc-trap’ method has been one of
the most commonly applied techniques for the detection of H2S.
This assay relies on trapping sulﬁde with a metal (e.g., zinc acetate)
with subsequent acidiﬁcation and reaction with N,N-dimethyl-p-
phenylenediamine (DMPD) to form methylene blue that is mea-
sured using a spectrophotometer or plate reader at 670 nm. Fischer
et al. initially reported this method primarily aimed to measure
sulﬁde levels in aquatic samples [39]. Many modiﬁcations of this
method have been made over the years for analyzing non-biologi-
cal samples – mainly sewage and seawater [40–45]. A direct spec-
trophotometry based ultraviolet detection of sulﬁde has been
reported previously from aquatic or environmental samples and
not best suited for blood, tissue and other biological specimens
[46], [47]. There are several critical issues with this method when
applied to biological specimens including:
(i) interference with colored substances formed as sulﬁde
reacts with N,N-dimethyl-p-phenylenediamine sulfate in
the presence of the oxidizing agent Fe3+,
(ii) strong chemical pretreatments (i.e., acids) of this method
lead to liberation of H2S from other forms of sulﬁde (e.g.,
acid labile pools) that can contribute to erroneous
measurements,
(iii) lack of sensitivity to low (physiological) H2S concentrations
and absence of distinct absorption peaks at 670 nm,
(iv) dimer and trimer formation of methylene blue with high
absorption spectra at 667 nm where it does not obey Beer’s
law contributing to erroneous results,(v) time dependent nature of color formation and intensity that
requires consistent and careful monitoring,
(vi) and that this method does not control for factors inﬂuencing
sulﬁde stability such as pH or O2 concentrations.
In spite of these limitations and resulting disparate sulﬁde mea-
surements, it is surprising that this method is still widely used to
measure H2S levels.
While our group and others have raised the above concerns
regarding the use of the methylene blue based assay
[33,36,37,48,49]; we have unequivocally demonstrated that the
methylene blue assay does not produce a bona ﬁde hydrogen sul-
ﬁde peak (660–680 nm) at low expected physiological concentra-
tions unlike other analytical detection methods (e.g., HPLC
detection of sulﬁde-di-bimane) [36,37]. Our ﬁndings along with
that of others demonstrate that the methylene blue method may
only be suitable for measuring H2S in simple aqueous solutions
and highlights the limitation of the methylene blue method for
detection of sulﬁde in complex biological matrices. However, there
are several other analytical techniques for measuring biological
H2S levels including gas/ion chromatography, HPLC, polarographic
sulﬁde detectors, mass spectrometry and ﬂuorescent probes.
Sulﬁde-speciﬁc ion-selective electrodes (ISEs)
ISEs have also been in use to detect H2S levels in biological sam-
ples, with a detection range of 1–10 lM. Though this method is
readily available and easy to operate, it too has its ﬂaws in detect-
ing biological sulﬁde levels. ISEs measure the S2 form of sulﬁde
that requires an alkaline environment to favor the S2 equilibrium,
which may contribute to erroneous sulﬁde readings. Whitﬁeld
et al. have demonstrated this erroneous affect of ISEs using Trout
plasma and bovine serum albumin (BSA) samples [50]. They
showed that sulﬁde levels of BSA and trout plasma samples placed
in alkaline buffer rapidly increased over time reaching 1 mM by
12 h. Searcy and Lee reported that the lower detection limit to be
0.5 lM and claimed that the electrode can work in oxygenated
and deoxygenated buffers equally [11]. However, its application
to biological samples is questionable considering the potential
for erroneous measurements due to strong chemical pretreatment
of samples.
Polarographic electrodes
Polarographic H2S sensor detection is well documented and a
reliable method to measure H2S levels as reported by Kraus and
colleagues and the Olson laboratory. Polarographic H2S detection
can be employed for real-time measurement of H2S gas from bio-
logical samples, with a lower detection limit in the nM range un-
der anoxic conditions [51]. With this approach, endogenous
sulﬁde levels have been reported in the low lM range (<5 lM)
in rat whole blood and in rat aorta (5–40 lM) [52]. However,
using the polarographic H2S sensor approach Whitﬁeld et al. re-
ported that sulﬁde was undetectable in plasma and blood col-
lected from various animal sources. They observed that plasma
and blood levels were relatively undetectable (<100 nM total sul-
ﬁde) and only observed a slight increase in H2S (low lM), upon
exogenous application of a sulﬁde donor that was rapidly cleared.
This is in stark contrast to other reports estimating physiological
sulﬁde concentrations between 10 and 300 lM using the methy-
lene blue method. From a historical perspective, speaking with
various investigators employing polarographic electrodes early
on, many of these custom built electrodes used a unique silicone
polycarbonate blend membrane (most likely M213 membrane
initially designed by General Electric silicones) that is no longer
commercially available. While it is not clear whether current
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apparent from investigators using these probes that the sensitiv-
ity and longevity of newer polarographic electrodes are some-
what different from that of previous reports. Nonetheless, a
recent report by Faccenda et al. has sought alternative ap-
proaches and demonstrated that polydimethylsiloxane (PDMS)
membranes are quite permeable to H2S and useful in construct-
ing devices for continuous measurement of H2S [53]. Though
the H2S polarographic sensor method is very sensitive and accu-
rate; it is not capable of detecting other biochemical forms of sul-
ﬁde (e.g., acid labile and bound sulﬁde). Additionally, processing
of samples to preserve the sulﬁde content for later polarographic
measurement has not been routinely reported as this method ap-
pears best suited for immediate real time measurement of H2S
production.Chromatography methods
Chromatography detection methods for H2S include gas, ion-ex-
change chromatography and variants of HPLC for detection of var-
ious pools of sulﬁde from biological samples. Tangerman et al. have
reported a GC based technique for measuring volatile sulfur com-
pounds in human breath using a speciﬁc sulfur detector with a
detection limit of about 0.2 ng/l (0.1 ppb) [38]. Likewise, Ubuka de-
vised a technique to measure sulﬁde pools using gas chromatogra-
phy with a ﬂame photometric detector (GC-FPD) and ion
chromatography (IC), and measured hydrogen sulﬁde and acid-la-
bile sulfur in rat liver and heart tissues [21]. An acid-labile sulﬁde
value of 100 nmol/g tissue was reported with no detectable free
sulﬁde. Goodwin et al. have measured sulﬁde levels in human
and rat brain tissue through gas dialysis/ion chromatography in a
range of 100 lM [54]. Furne et al. have used a combination of
gas chromatography with a chemiluminescence sulfur detector to
detect free H2S levels with a low detection limit in the nM range
[55]. With this method, very low levels of free H2S were measured
in mouse brain (14 nM) and liver tissue (17 nM) and in human
blood at an estimated 100 pM. Ishigami et al. have developed a
GC based method using silver particles to trap free H2S from the
rat brain homogenate, with a low lM (9 lM) detection limit
[19]. In addition they also reported other storage forms of sulﬁde,
acid-labile and bound, in the lM range. Lastly, Levitt et al. have re-
ported the concentration of mouse blood H2S in the range of 15 nM
using a combined GC/chemiluminscent detection method [56].
These approaches are clearly sensitive and speciﬁc, but may be
viewed as less ‘user-friendly’ due to the analytical equipment
needed impacting the likelihood of these methods being used.
Moreover, different specimen collection and processing methods
likely contribute to the reported levels as these methods primarily
facilitate detection of H2S gas alone versus other bioavailable forms
of sulﬁde (e.g., HS, acid labile sulﬁde and bound sulfane sulfur).
High pressure liquid chromatography analysis has been em-
ployed by several laboratories to measure bioavailable sulﬁde in
various forms. Using RP-HPLC detection of methylene blue, Savage
and Gould used zinc acetate to trap and measure H2S levels in
brain tissue homogenized under acidic conditions [57]. Ogasawara
also previously reported a ﬂuorescence-based HPLC approach,
derivatized with p-phenylenediamine and Fe3+ to measure H2S lev-
els by converting it to thionine [18]. Monobromobimane (MBB), a
thiol sensitive ﬂuorescent probe, has been reported by Newton
and Fahey and Togawa et al. to measure bioavailable H2S [58,59].
In this assay the H2S/HS speciﬁc sulﬁde-diamine product is mea-
sured through HPLC coupled with ﬂuorescence detection. This
method is very sensitive and speciﬁc but does require the use of
HPLC equipment and procedures that may be unavailable to some
investigators.Recent reports have further examined the MBB assay for H2S
detection providing greater detailed information regarding this
approach as a highly useful method for sulﬁde detection. Wintner
et al. employed the MBB protocol under derivatization conditions
at pH 8.0, and observed free H2S levels in rat blood to be around
0.7 lM [60]. We further reﬁned the MBB assay identifying ideal
optimal pH and oxygen concentration ranges that enable consis-
tent and reliable measurement of H2S bioavailability with a detec-
tion limit of low nM [37]. Using this protocol that carefully
controls for pH, oxygen tension, and the presence of metals; we
ﬁnd that human plasma free H2S/HS levels are in the mid nano-
molar range (300–500 nM) and that mouse plasma free H2S/HS is
in the low micromolar range 1.0 lM. It is important to under-
stand that the MBB assay measures all bioavailable sulﬁde in
the gas and anion form (H2S/HS), which are both biochemically
active, yielding a comprehensive measurement of H2S bioequiva-
lents in biological specimens. We have further adapted the MBB
assay to measure other biochemical forms of bioavailable sulﬁde
contained within acid labile and bound sulfane sulfur pools [36].
Using this new method, we found the acid labile pool of sulﬁde
(which contains Fe–S cluster proteins and persulﬁdes) to be the
most abundant in plasma (2–4 lM) in both mice and man;
whereas the free and bound sulfane sulfur pools were consider-
ably lower in the nanomolar range. These combined approaches
employing measurement of different sulﬁde biochemical forms
represents a powerful and very useful method with which to eval-
uate biological H2S bioavailability under different pathophysiolog-
ical conditions, as illustrated by our recent ﬁndings on microbiota
regulation of sulﬁde biochemical pool bioavailability in all the ma-
jor organs of the mouse [61].Fluorescent probes for H2S detection
Due to numerous cellular signaling and therapeutic implica-
tions of H2S, signiﬁcant attention has been given to devising novel
methods for sensitive and real-time H2S detection within speciﬁc
tissue and cellular compartments. Recently, single-walled carbon
nanotube (SWNT) networks and Quantum Dot (QD) ﬂuorescence
techniques have been reported to detect H2S as low as 3 ppb [62]
and 0.15 lM [63], respectively in non-biological systems. Both of
these approaches are highly selective and sensitive to H2S/HS.
Thus, use of this type of detection approach may be informative
for evaluating cellular H2S production. Along these same lines,
Liu et al. and Peng et al. have developed a ﬂuorescence-based strat-
egy for detection of H2S [64,65]. In their method, Liu et al. have
measured the concentration of H2S in plasma by assessing the ﬂuo-
rescence signal from benzodithiolone product formation; whereas,
Peng et al. synthesized a novel reduction-sensitive, stable non-
ﬂuorescent chemoprobe, dansyl azide (DNS-Az), that becomes
ﬂuorescent upon reacting with sulﬁde. Though these ﬂuorescent
H2S detection methods are very simple and cost-effective, possible
limitations may exist in the sensitivity of H2S detection (micromo-
lar) and the time needed to sufﬁciently detect changes in H2S levels
(several minutes to an hour). Moreover, some of the reported ﬂuo-
rescent dyes have excitation-emission wavelengths (490–700 nm)
near tissue autoﬂuroescence wavelengths that could make sensi-
tive and/or selective detection of low sulﬁde concentrations difﬁ-
cult. Finally, this technical approach is currently not able to
measure sulﬁde levels from different biochemical pools within
the sample or account for the fact that H2S can be quickly scav-
enged by proteins [36,37], that could inﬂuence the signal obtained
from biological samples. However, the non-reactive nature of these
dyes with other biological thiols (e.g., cysteine and glutathione) is a
strength along with the ease of sample analysis highlighting vari-
ous beneﬁcial aspects of these approaches.
Table 1
Comparisons of commonly used H2S detection methods.
Method Advantages Disadvantages Reference
Direct spectophotometric measurement – Low background – Micromolar detection limit (1 lM)
– Potential absorption interference
[46,47]
Gas chromatography/ﬂame photometric
detector (FPD)
– Sensitive/selective detection (ppb) – Multiple steps need to measure
– Difﬁcult to determine different forms
[14,55,56]
Ion chromatography – Sensitive detection (30 ppb) – Poor conductivity
– Limited through put
[14,54]
Polaragraphic sensor (H2S electrode) – Sensitive detection (10nM)
– Easy to use
– Real time detection
– Limited through put
– Limited detection of different forms
[51,52]
Gas chromatography/chemiluminescence – Sensitive detection (nM–pM) – Chemiluminescence detects total sulfur
– Limited through put
[38,56]
Methylene blue assay – Easy protocol, performed in most reported stud-
ies of H2S
– Limited detection sensitivity; low-mid lM
– Prone to contamination from acid labile sul-
fur pools
– Possible color interference
[41–45]
Fluorescent probe of H2S – Easy protocol
– Direct visualization of production
– Moderate detection sensitivity (lM)
– Possible substance interference
– Prolonged incubation time
– Limited detection of different forms
[62–65]
Monobromobimane derivatization/HPLC – Sensitive detection (nM)
– High through put
– Stable derivative
– Can measure multiple biochemical pools
– Requires RP HPLC [36,37,60]
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In the past, remarkably high levels of H2S have been reported
using techniques that are increasing understood to be prone to er-
ror and artifact (e.g., the methylene blue assay). However, as with
any approach or method, speciﬁc experimental details or questions
must be carefully considered before embarking upon a study.
Although, as we have discussed above, there are strengths and
weaknesses to the various methods used to measure H2S bioavail-
ability. Table 1 provides a distilled comparison between these
methods along with useful references for the reader. However,
there are additional important experimental details for consider-
ation that include but are not limited to: (1) sensitivity – what lev-
els of H2S detection are required or desired? (2) Technical
capability – what equipment or resources are available to perform
various measurement techniques? (3) Specimen type – biological
ﬂuids, tissue, exhaled gases or breath? (4) Temporal requirements
– is constant real time measurement necessary or will a single time
point sufﬁce? It is important to remember that the measurement
method used will also inﬂuence results such that using a method
that only measures H2S in the gaseous phase will not accurately
represent bioavailable sulﬁde equivalents that may exist in the an-
ion form (HS) that are still biologically active and measurable
using different approaches. Considering both experimental details
along with understanding speciﬁc method capabilities and limita-
tions will signiﬁcantly aid both the investigator and the ﬁeld of H2S
research in its quest to learn more about this gasotransmitter.
Biological functions of sulﬁde
Knowledge of the biological roles for endogenous H2S is con-
stantly expanding. Many studies in the literature indicate that
H2S executes physiological effects at a wide range of concentra-
tions between 10 and 300 lM [66]. However, it is important to
keep in mind that many of these levels were determined using old-
er detection methods versus newer, sophisticated analytical ap-
proaches. Nonetheless, it is clear that H2S is involved in
modulating various physiological responses including anti-inﬂam-
mation [67], reducing oxidative stress [68], neuromodulation [4],
vasoregulation [69], protection from reperfusion injury after myo-
cardial infarction [70], and inhibition of insulin resistance [71].
Moreover, many researchers continue to explore this signalingmolecule for its involvement in various aspects of cell function,
cytoprotection and cellular signaling.
Vasodilation and anti-hypertensive effects
Nitric oxide (NO) is a well established signaling molecule acting
as an endothelium-derived relaxing factor (EDRF) of the vascula-
ture. However, recent studies have shown evidence that H2S also
acts as a relaxing factor of blood vessels involving alteration in
K+ channel activity and elevated cGMP levels in vascular smooth
muscle cells (SMCs) similar to NO [72,73]. Li et al. demonstrated
in a renal hypertension rat model that the H2S donor NaHS relaxes
vascular smooth muscle, causes rapid and reversible relaxation of
isolated aortic rings, and dilates the perfused renal vasculature
by opening KATP channels of vascular smooth muscles cells. They
also observed reduced hypertension levels mediated by the H2S
donor in a dose dependent manner [74]. Moreover, other investiga-
tors have reported that H2S mediates vasorelaxation through KATP
channels in vascular SMCs such that inhibtion by glibenclamide
blocks H2S-induced dilation of aortic rings, the mesenteric artery,
and hepatic microvasculature [75–77]. Bucci et al. have also attrib-
uted H2S vasodilatory effects to the cGMP pathway [78]; while,
Zhao et al. indicated that cGMP pathways were not involved in this
response [75]. Although speciﬁc mechanisms remain unknown, it
is clear from these studies that H2S plays a prominent role in reg-
ulating endothelium-dependent vasoactive activities.
Consistent with the above ﬁndings, diminished H2S levels are
associated with constriction of blood vessels, thus increasing blood
pressure. Yang et al. have reported that genetic deletion of the H2S
generating enzyme cystathionine c-lyase (CSE) leads to the devel-
opment of hypertension [72]. Supporting this study, Benavides
et al. have shown that garlic relaxes rat aortic rings through an
endothelium-independent and H2S dependent mechanism [79].
They demonstrated that garlic-derived organic polysulﬁdes via
glucose and thiol-dependent mechanisms release H2S, which
causes the vasorelaxant effect in rat aortic rings. Similar conclu-
sions were drawn from the work of Ashraf et al. demonstrating
an endothelium-dependent vasodilator response by garlic in a
NO/cGMP dependent manner [80]. These ﬁndings are consistent
with previous studies showing that low doses of the H2S donor
NaHS produced short-lived relaxation to mesenteric artery and
intestinal contractility [76,81]. Interestingly, however, higher
12 G.K. Kolluru et al. / Nitric Oxide 35 (2013) 5–20doses of NaHS caused a biphasic relaxation/constriction response, a
response that warrants further investigation [76]. In summary, it is
clear that H2S acts as an effective vasodilator and subsequent
reduction of blood pressure, yet more studies are needed to under-
stand speciﬁc cellular and signalling mechanisms regulating these
responses.
Anti-inﬂammatory effects
It is well known that nonsteroidal anti-inﬂammatory drugs
(NSAIDs) induce gastroenteropathy [82]. Research suggests that
NSAIDs suppressed endogenous H2S synthesis by reducing expres-
sion of CSE. The accompanying reduction of H2S synthesis may in
turn contribute to an increase in leukocyte adherence resulting
in gastric injury that is seen after NSAID administration [83–85].
Similarly, administration of exogenous H2S reduced the ability of
these agents to cause gastric injury. Fiorucci et al. have also found
that exogenously supplied H2S suppressed NSAID-induced granu-
locyte inﬁltration, expression of endothelial and leukocyte adhe-
sion molecules, and expression of tumor necrosis factor a (TNF-
a) [82]. It was found that leukocyte adhesion to the vascular endo-
thelium induced by aspirin injury was decreased after increasing
H2S bioavailablity and that CSE inhibition with propargylglycine
exacerbated asprin mediated mucosal injury and inﬂammation
[82]. This study also observed that leukocyte expression of LFA-1
was suppressed by exogenous H2S. Interestingly, this article also
showed a molecular aspect of H2S induced anti-inﬂammatory ef-
fects, such that H2S donors decreased aspirin-induced leukocyte
adhesion through the activation of KATP channels and inhibition
of CSE activity that promotes leukocyte adhesion. Additional stud-
ies demonstrated that coadministration of an H2S donor with an
NSAID resulted in inhibition of NSAID-induced leukocyte adher-
ence and reduction of the severity of gastric damage [86,87]. In
contrast, irreversible inhibition of CSE can attenuate the severity
of experimental pancreatitis [88] and endotoxemia [89]. These re-
sults demonstrate that H2S donors can down-regulate adhesion
molecule and proinﬂammatory cytokine expression, therefore
identifying H2S, its synthesis enzymes, and molecular targets
(e.g., KATP channels) as potential targets for novel anti-inﬂamma-
tory therapies.
Anti-oxidant effects
Cells can be protected from oxidative stress through numerous
mechanisms with intracelluar glutathione dependent or indepen-
dent pathways serving as primary mediators [90]. Evidence in sim-
ple uni or multicellular organisms reveals that sulfur containing
substances dimethylsulphoniopropionate and dimethylsulﬁde act
as endogenous scavangers of reactive oxygen species in marine al-
gae [91]. However, in more complex organisms it has been ob-
served that H2S exerts its antioxidant effect not directly but
through induction of glutathione metabolism responses [1]. This
is conﬁrmed by a recent study by Hamar et al. demonstrating that
H2S itself is a rather poor antioxidant compared to other antioxi-
dant defenses [92]. Jha et al. have also shown that hydrogen sulﬁde
protects hepatocytes from ischemia reperfusion (I/R) injury
through up regulation of intracellular antioxidants [7]. Likewise,
Calvert et al. have reported that exogenous H2S confers cardiopro-
tection against I/R injury through Nrf-2 induction [26]. Conversely,
it has been shown that oxidative stress is increased by decreased
endogenous production of H2S in hypoxic pulmonary hypertensive
rats [93]. Moreover, H2S enhances the activity of cysteine and cys-
tine transporters to increase the level of substrates for glutathione
(GSH) production. H2S produced by 3-mercaptopyruvate sulfur-
transferase (3-MST) along with catalase may also directly suppress
oxidative stress in mitochondria. H2S also attenuates oxidativeinjury in astrocytes by H2O2 by increasing glutamate uptake [94].
H2S can also inhibit peroxynitrite-mediated tyrosine nitration of
neuronal proteins, suggesting that H2S has the potential to act as
an inhibitor of peroxynitrite-mediated processes in vivo [70]. Evi-
dence also indicates that H2S increases the ability of the antioxi-
dant enzyme superoxide dismutase to scavenge superoxide and
increase the level of GSH biosynthetic enzyme c-glutamylcysteine
synthase [95]. Lastly, it is well known that H2S modulates mito-
chondria function, as it is a potent and reversible inhibitor of cyto-
chrome c oxidase. Through this ability to blunt cellular respiration,
which in turn reduces mitochondrial ROS production and de-
creases mitochondrial uncoupling, H2S can elict cytoprotection
[96]. However, the protective dose range of H2S against mitochon-
drial uncoupling and ROS formation compared to NO is much nar-
rower likely due to the fact that posttranslational modiﬁcations
due to H2S/HS- are more difﬁcult to biochemically reverse com-
pared to nitros(yl)ation. Together, the majority of evidence sug-
gests that H2S production and bioavailability potently regulate
cellular redox status through antioxidant defense responses versus
direct antioxidant activity.
Cytoprotection/anti-apoptosis effects
Hydrogen sulﬁde exerts anti-apoptotic effects in different or-
gans but many studies of this nature have been performed in I/R
injury of the heart. It has been shown that H2S attenuated cardiac
myocyte apoptosis subjected to myocardial I/R in vivo [26]. Sodha
and colleagues reported that H2S exerts its anti-apoptotic effect by
inactivation of caspase-9 caused by I/R [97]. Sivarajah et al. have
further demonstrated that administration of 5-hydroxydecanoate
(5-HD), a KATP channel blocker, abolished the attenuation in cardiac
myocyte apoptosis and caspase-9 activity caused by H2S [70]. Com-
plementary to the attenuation in caspase-9 activity, H2S also ame-
liorated the expression of Bcl-2 protein caused by regional
myocardial I/R that was abrogated by 5-HD. Thus, these results
indicate that H2S mediates signiﬁcant anti-apoptotic effects, which
may be secondary to the opening of putative mitochondrial KATP
channels [70]. Likewise, inhalation of H2S before ischemia has been
shown to decrease retinal I/R injury and cell loss through attenua-
tion of caspase-3 cleavage and activity, thereby decreasing apopto-
sis [98]. Lastly, Shi et al. have shown that the attenuation of
cardiomyocyte apoptosis by H2S is associated with early inhibition
of JNKs during reperfusion, increased Bcl-2/Bax expression ratio,
and diminished cytochrome c release [99]. Thus, all of the above
ﬁndings demonstrate that H2S induces cytoprotection by an anti-
apoptotic pathway.
Fibrinolytic activity
Inhibition of ﬁbrinolytic activity or deﬁciency of the factors in-
volved might upset the hemostatic balance and allow excessive ﬁ-
brin deposition especially in diabetes, hypertension and
hypercholesterolemia. One study has shown that a marked rise
in blood coagulation of hypercholesterolemic rabbits was signiﬁ-
cantly reduced by the essential oils of garlic. They also observed
that ﬁbrinolytic activity was actually increased even above the nor-
mal control levels, which were mediated by the essential oils of
garlic [100]. The plasma ﬁbrinolytic activity in rabbits, which
was decreased upon cholesterol feeding, was considerably in-
creased when this diet was supplemented with garlic [101]. Stud-
ies on ﬁbrinolytic activity of garlic in humans have shown
increased ﬁbrinolytic activity and inhibition of platelet aggregation
[102]. Acute as well as chronic intake of garlic oil and raw garlic in-
creased ﬁbrinolytic activity. Earlier studies from Bordia et al. also
demonstrated that garlic oil increased ﬁbrinolytic activity after
3 h of administration [100]. They further reported that chronic
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cantly in healthy as well as acute myocardial infarction patients
[100,103]. Other studies have similarly suggested that both raw
and fried garlic signiﬁcantly enhances ﬁbrinolytic activity in hu-
man plasma [104,105].
Anti-platelet activation and aggregation effects
Platelet aggregation superimposed on an atherosclerotic vessel
is an antecedent event causing total blockage of blood ﬂow leading
to myocardial infarction and thromboembolic diseases such as
peripheral arterial disease. In animal studies, pre-treatment of rab-
bits with an aqueous extract of garlic signiﬁcantly inhibited throm-
boxane-B2 (TXB2) synthesis (a potent platelet aggregator) and
protected against thrombocytopenia induced by collagen or ara-
chidonate infusion. These observations indicate that garlic and its
associated H2S may be beneﬁcial in the prevention of thrombosis
[106]. Aqueous extract of garlic was found to inhibit platelet aggre-
gation induced by ADP, epinephrine, collagen and arachidonate in
a dose-dependent manner in vitro and to inhibit biosynthesis of
prostacyclin in rat aorta [107]. A dose-dependent inhibition of
cyclooxygenase activity and collagen-induced platelet aggregation
was observed in rabbit platelets treated with raw garlic in vitro
while boiled garlic was found to have little effect [108]. Garlic ex-
tract containing diallyl disulﬁde and diallyl trisulﬁde, prevent
acute platelet thrombus formation in stenosed canine coronary
arteries [109]. Fresh garlic extract is effective in reducing throm-
boxane formation by platelets both in vivo and in vitro in models
of thrombosis. It was observed that garlic inhibits thrombin-in-
duced platelet synthesis of TXB2 in a dose and time-dependent
manner in rabbits. The rapid recovery of platelet cyclooxygenase
activity after infusion of a single dose of garlic suggested that garlic
be consumed frequently in order to achieve beneﬁcial effects of
limiting thrombosis [110]. In human studies, a positive response
to garlic inhibition of thrombosis has also been observed. Like
enhancement of ﬁbrinolysis, garlic also attenuates platelet adhe-
sion or aggregation in humans. Bordia and his colleagues ﬁrst
showed the dose-dependent inhibition of platelet aggregation by
garlic [111]. Raw garlic, garlic oil and other extracts of garlic have
been shown to inhibit platelet aggregation in vitro induced by ADP,
collagen, arachidonate, epinephrine and calcium ionophore in hu-
mans [112]. Chronic intake of garlic powder and garlic oil also
inhibits platelet aggregation in humans [113]. Moreover, the effect
of garlic on platelet function is also acute in that a single dose of
garlic can inhibit platelet aggregation in humans [114]. Recently,
Allison et al. have demonstrated that garlic extract inhibition of
platelet activation and aggregation can be attributed to increased
platelet cAMP levels and inhibition of GPIIb/IIIa (aIIbß3), an inte-
grin that promotes platelet-platelet aggregation [115]. These ﬁnd-
ings together with the ﬁbrinolytic effects of garlic and its extracts
suggest that H2S bioavailability may play an important role in reg-
ulating platelet function and thrombosis. However, it is not yet
precisely clear whether garlic dervied H2S is truly responsible for
the beneﬁcial effects observed or whether endogenous H2S metab-
olism responses exert equally important roles in regulating platelet
function and thrombosis.
Pro-angiogenic effects
Angiogenesis is a regulated process of microvascular growth
that is often invoked to revascularize ischemic tissues of many or-
gan systems. Likewise, angiogenic activity may also serve patho-
logical roles through its regulation of chronic inﬂammation and
tumorigenesis [116,117]. Our laboratory and other investigators
showed that H2S modulates angiogenesis responses in vitro by
enhancing endothelial cell proliferation and migration [118–120].In these studies, researchers found that lowmicromolar concentra-
tions of H2S in the form of Na2S or NaHS increases endothelial cell
growth, migration and formation of tube-like structures in cul-
tured endothelial cells [118–120]. Bir et al. demonstrated that
H2S stimulates endothelial cells more potently under hypoxia than
normoxia suggesting that H2S plays a more dominant role for angi-
ogenesis under hypoxic conditions [118]. Similarly, NaHS treat-
ment also seems to increase the proliferation and migration of
vascular smooth muscle cells under hypoxic conditions [121].
Hydrogen sulﬁde also promoted neovascularization in vivo in
the mouse, as well as in chicken chorioallantoic membranes
[119,120]. Subsequent studies from our group have shown that
H2S signiﬁcantly promoted angiogenesis and improved regional
blood ﬂow in ischemic limbs, which indicate microvascular growth
in ischemic tissues [5]. This effect of H2S is mediated through up-
regulation of HIF-1/VEGF/Akt mediated pathway in vascular endo-
thelial cells [118,119,121]. Our study showed that H2S restores
blood ﬂow in ischemic tissue via an NO/HIF-1/VEGF dependent
pathway [118]. A recent study by Tao et al. further showed that
VEGFR2 acts as a receptor for H2S during angiogenesis [122]. Like-
wise, it has also been reported that down regulation of VEGFR2
during ischemia was reversed by H2S with speciﬁc phosphoryla-
tion at Tyr 996 of the receptor [5]. Cai et al. ﬁrst suggested that
H2S exerts its angiogenic effect by enhancing Akt phosphorylation,
which was attenuated by PI-3 kinase inhibitor suggesting that PI3K
is upstream of Akt in underlying H2S signaling mechanism [119].
Further study showed that H2S upregulates the phosphorylation
of ERK 1/2 and p38 and this effect was attenuated by MAPK indi-
cating the involvement of MAPK/ERK pathway in H2S mediated
angiogenesis [120]. It has also been reported that KATP channels
partially mediate the angiogenic effects of H2S [5,118] in that
selective and non-selective KATP channel blockers attenuated p38
and hsp27 phosphorylation [120]. Lastly, a recent study by Wang
et al. reported that CSE activity and function is critically important
for healthy placental vascular growth and development during
pregnancy by controlling levels of antiangiogenic molecules sFlt-
1 and sEng [123].
H2S may also regulate angiogenesis through other mechanisms
via participation of other molecules, such as NO and CO [124]. Our
group and others have reported that H2S stimulates angiogenesis
via enzymatic and non-enzymatic NO generation dependent path-
ways [118,125]. Moreover, Bucci et al. reported that H2S increases
cGMP in smooth muscle cells through inhibition of phosphodies-
terase (PDE) activity [78]. This effect of H2S subsequently induces
both endothelial proliferation and migration under hypoxic condi-
tions. Fig. 3 summarizes the various signalling pathways whereby
H2S can regulate angiogenic activity. However, further studies are
needed to better understand cooperative mechanisms necessary
for proangiogenic effects of H2S.
Cardioprotective effects (MI and I/R)
Several studies in vitro and in vivo have suggested that H2S has a
cardioprotective effect [70,96,97,126]. DL-propargylglycine (PAG),
a CSE inhibitor, blocks this protective effect by inhibiting endoge-
nous H2S production. There is an inverse relationship with H2S
and MI. Zhu and his colleagues have demonstrated that decreased
infarct size and mortality are linked to elevated plasma H2S con-
centrations after MI, and the opposite, where decreased H2S levels
in the plasma were associated with an increased infarct size and
mortality [127]. Their study also showed that inhibition of endog-
enous H2S had a negative consequence on the cell viability. A sim-
ilar study by Bian et al. showed that exogenously administered H2S
improved cardiac rhythm, cell viability and function in MI rats
compared to the vehicle, whereas PAG administration worsened
these effects [128].
Fig. 3. Interactions of H2S and NO signaling pathways. H2S and NO have common signaling that include upstream molecules such as VEGF, HIF-1a, AKT, eNOS and XO
mediated nitrite reduction to NO under ischemia; downstream signaling involves cGMP/PKG, Ras/Raf and MEK/ERK pathways leading to vascular remodeling. NO and H2S
possibly react chemically to form novel compounds such as S-nitrosothiol (SNO), nitroxyl (HNO), simple form of S-nitrosothiol (HSNO) and sulﬁnyl nitrite FS(O)NO.
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tems. It protects the heart during I/R injury, both in pre- and post-
conditioning. In post-conditioning, H2S protects the heart by differ-
ent mechanisms. Zhang et al. reported that H2S protects the heart
against I/R injury by opening K-ATP channels [126], which is sup-
ported by similar studies [70,127,129]. Another report has sug-
gested that ischemic preconditioning with H2S also involves PKC
and K-ATP channels [128]. H2S also protects the heart by activating
Nrf-1 and Nrf-2 mediated Akt phosphorylation that ultimately re-
duces the oxidative stress in cardiomyocytes [130]. Besides, H2S
also involves eNOS related Akt phosphorylation that stimulates
angiogenesis resulting in cardioprotection [119,131]. Likewise,
H2S protects the heart by increasing NO bioavailability and block-
ing nitric oxide synthase activity or function attenuates H2S in-
duced cardioprotection in mice [132–134].
Recent study by Qipshidze et al. showed that H2S induces cyto-
protection and angioprotection during MI to protect the heart by
increasing the expression of VEGF, ﬂk-1, ﬂt-1 and simultaneously
decreasing endostatin, angiostatin and parstatin expression [135].
Anti-apoptosis signaling such as modulation of Bcl-2, decreased
expression of Beclin-1 and alteration of phosphorylation of stress
activated proteins are also involved in H2S mediated cardioprotec-
tion [136]. Research also suggests that H2S preserves both the
structure and function of mitochondria and inhibits cellular respi-
ration by blocking cytochrome c oxidase leading to protection
against myocardial ischemic injury [137,138]. It was also observed
that H2S protects cardiomyocytes through Ca2+ channel and cAMP/
PKA pathway mediated inhibition of myocardial contractility[139]. Similarly, H2S induces cardioprotection by preventing Ca2+
overload in the ischemic heart by suppressing Na+/H+ exchanger
-1 involving PI-3K/ Akt/PKG dependent pathway [140]. The PDE-
5 inhibitor, tadalaﬁl, induces cardioprotection by PKG dependent
production of H2S in ischemic heart [141]. Preconditioning with
H2S in I/R injury also protects against myocardial injury. Decreased
c-Fos protein, improved cytosolic Ca2+ in a PKC dependent path-
way, activated Nrf2 signaling, activated ERK and PI3k/Akt path-
ways are observed mechanisms of H2S induced (preconditioned
with H2S) cardimyocyte protection during I/R injury [26,142–
144]. Thus, therapeutic application of H2S may be beneﬁcial in var-
ious cardiac diseases.
Metabolic suppression
It has been reported that H2S may serve as an oxygen sensor in
many cell types in various species [4,35,50]. Studies have further
demonstrated that H2S can reduce metabolic demand for oxygen
by depressing mitochondrial function and inhibiting the cellular
oxygen receptors [145–147]. The resulting effect is a reduction of
cellular metabolism leading to a state of hibernation. Studies from
the Roth laboratory have demonstrated that 80-ppm H2S induced
metabolic depression in mice [147]. Additionally, Volpato et al. re-
ported that H2S induces a reduction of metabolic rate that revers-
ibly depresses cardiovascular function without effecting blood
pressure in mice [148]. These observations suggest that H2S may
be useful to prevent cellular damage associated with hypoxia,
hemorrhagic shock or brain injury. However, these responses are
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ported that H2S could not improve survival or protect from hemor-
rhagic shock in piglets [149]. Further study in this area is needed to
better understand the effects of H2S on tissue metabolism and the
associated mechanisms involved.
Atherogenesis
As discussed above, CBS is a primary enzyme producing H2S.
Deﬁciency of CBS enzymatic activity leads to decreased production
of H2S as well as development of hyperhomocysteinemia. Studies
demonstrate that hyper-homocysteinemia in turn leads to forma-
tion of premature atherosclerosis via the promotion and sustained
injury of endothelial cells, and inducing vascular smooth muscle
cell proliferation [150,151]. In addition, increased homocysteine
may impair generation and bioavailability of EDRF/NO, endothe-
lium-dependent vasodilation, interfere with many transcription
factors and signal transduction, and oxidize low-density lipopro-
teins that lead to formation of atherosclerotic plaque [152,153].
Hyperhomocysteinemia has a strong correlation with premature
peripheral, cerebral and coronary arterial disease following athero-
sclerosis [154]. Moreover, these effects of hyperhomocysteinemia
can be reversed by H2S therapy highlighting the importance of this
molecule in regulating different pathophysiological events in this
process [155,156].
Importantly, H2S levels have been reported to be inversely re-
lated to plasma lipid levels in healthy individuals [157]. However,
the precise levels of plasma and plaque H2S levels and its biochem-
ical forms remain poorly understood in patients with various forms
of vascular disease and requires further study. Nonetheless, it has
been recently identiﬁed that endogenous sulﬁde generation
through CSE activity critically regulates the progression of experi-
mental atherosclerosis. Work from Mani et al. found that genetic
deﬁciency of CSE signiﬁcantly enhances atherosclerosis develop-
ment in ApoE knockout mice involving disruption of vascular redox
status, increased intimal proliferation and inﬂammatory adhesion
molecule expression [158]. H2S can also inhibit calciﬁcation and
osteoblast differentiation of vascular smooth muscle cells, that
can contribute to atherogenesis [159]. Furthermore, H2S has been
reported to blunt foam cell formation by down-regulating the
expression of CD36, SR-A and ACAT1 via the KATP/ERK1/2 pathway
and inhibiting oxLDL uptake in human monocyte-derived macro-
phages [160]. H2S containing aspirin therapy has been reported
to prevent the progression of atherosclerosis through down-regu-
lation of CX3CR1 in macrophages via PPAR-c dependent pathway
in apoE deﬁcient mice [161]. Exogenous H2S directly inhibits endo-
thelial cell adhesion molecule (i.e., ICAM, VCAM, E-selectin)
expression involving NF-kB, and protein kinase A and B signaling
pathways in concordance with atherosclerosis pathogenesis
[162,163]. H2S donors such as diallyl trisulﬁde (DATS) and diallyl
disulﬁde (DADS) protects from oxLDL induced vascular insults
and formation of atherosclerotic plaque by inhibiting eNOS degra-
dation, restoring eNOS-caveolin complex formation, and PKB
dependent eNOS activation [164]. Clearly, the ﬁeld of H2S and ath-
erogenesis is an exciting and challenging area that will continue to
grow and undoubtedly change the way we understand the patho-
physiological role of H2S for cardiovascular health.H2S interactions with NO and other biochemical moleculesModulation of enzymatic activity by gaseous molecules
As previously discussed, the functions and targets of NO and
H2S are closely related both physiologically and pathologically.Likewise, both NO and H2S are produced enzymatically by three
enzymes– nNOS/iNOS/eNOS for NO and CSE/CBS/3-MST for H2S,
with heme moieties playing a role in regulating functions of NOS
isoforms and CBS. These enzymes have speciﬁc ligands and cofac-
tors; and recent evidence suggests that there are interactions be-
tween NO, H2S and their enzymatic systems.
Hydrogen sulﬁde donors, DADS and DATS, can induce eNOS
activity through phosphorylation of Ser 1177 and PKB, subse-
quently increase NO production. This study further revealed that
DADS and DATS also prevented Ox-LDL mediated proteosome
dependent eNOS degradation [164]. Similarly, H2S stimulates the
AKT/eNOS pathway to preserve the cardiac contractile function
during ischemic post-conditioning [131]. Moreover, H2S activates
the eNOS/NO/P-38 MAPK pathway to prevent I/R injury [165]. In
another study, H2S was shown to potentiate the expression of iNOS
following stimulation with IL-1b in cultured rat vascular smooth
muscle cells [166]. In contrast, other studies revealed that H2S
inhibits nNOS and eNOS likely by altering interactions with BH4
and inhibiting iNOS through additional mechanisms [167,168].
Likewise, both in vitro and in vivo experimental studies showed
that H2S down-regulates the vascular L-arginine/NOS/NO pathway
[169,170]. Consistent with these reports, H2S has been reported to
alleviate pulmonary vascular remodeling by down-regulating
eNOS protein expression and decreasing NOS activity [171]. To-
gether, these data highlight that H2S regulation of NOS activity is
complex requiring further investigation into speciﬁc molecular
mechanisms.
Interestingly, NOS substrate or NO donors can up-regulate the
expression or activity of H2S producing enzymes [172,173]. Eto
and Kimura have demonstrated that exogenously applied SNP to
ex vivo rat brain cell suspensions increases CBS activity, although
independent of NO production [173]. L-arginine attenuates pul-
monary artery pressure by augmenting the expression of lung tis-
sue CSE mRNA as well as the activity of CSE in lung tissue [174]. In
contrast, studies also reveal that metabolites of NO (nitrite and ni-
trate) can reduce CBS enzyme activity during I/R of rat kidneys and
that CBS activity was restored upon treatment with cPTIO, an NO
scavenger [175]. Additional studies are needed to better under-
stand how H2S and NO may reciprocally regulate each others en-
zyme synthesis pathways.
Although, the relationship between NO and H2S may occur in a
reciprocal fashion, it is also evident that NOS/NO and CSE/CBS/H2S
pathways can mutually affect speciﬁc biochemical, cellular and
physiological functions in different organs. However, clear mecha-
nistic insight on H2S effects on NO/NOS system activity and vice
versa remains poorly deﬁned requiring further study.
Molecular target interactions of NO and H2S
Several reports indicate a potential synergistic effect between
NO and H2S in controlling various biological responses of vascular
function. Hosoki et al. showed that NO and H2S interact in a co-
ordinate fashion in regulating vascular tone [176]. Coletta et al.
found that NO and H2S mutually affect PKG to promote prolifera-
tion and angiogenesis in vitro [125]. This study revealed that inhi-
bition of NO production by blocking eNOS attenuated H2S-
mediated angiogenic activity under normoxic conditions and re-
duced H2S-dependent vasorelaxation highlighting the importance
of NO in vascular H2S signaling. Conversely, inhibition of H2S-pro-
duction through pharmacological inhibition of cystathionine-c-
lyase has been reported to diminish NO-stimulated cGMP accumu-
lation and angiogenesis, and attenuate acetylcholine-induced
vasodilation suggesting a role for H2S in the vascular activity of
NO [125]. Moreover, low concentrations of H2S (low micromolar)
signiﬁcantly enhance smooth muscle relaxation induced by NO in
the thoracic aorta indicating the role of endogenous H2S in
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ilarly, H2S may act in concert with NO in Stonustoxin-mediated
vasorelaxation, and the NO donor sodium nitroprusside can in-
crease H2S synthesis both in vitro and in vivo. [173,177]. NO donor
treatment of endothelial cells also augments cysteine uptake in a
dose dependent manner involving increased transporter synthesis
and activity, revealing how NO can regulate cellular H2S substrate
bioavailability in cells [178]. These ﬁndings combined with those
above suggesting reciprocal regulation make it difﬁcult to predict
a priori how H2S and NO would affect physiological and cellular re-
sponses although it is clear that these two gasotransmitters can
work in cooperative or antagonistic fashion.
Biochemistry of NO–H2S interactions
Hydrogen sulﬁde and NO may react under speciﬁc conditions to
form complex/novel species that display distinct biological func-
tions. A recent study revealed that NO donors, as well as NO gas
and a synthetic peroxynitrite (ONOO) react with H2S in vitro to
form nitrosothiol [179]. The authors posited that simultaneous
NO and H2S production in LPS treated rats could produce nitroso-
thiol in vivo. Likewise, studies showed that administration of NaHS
or inducing endogenous H2S production via cysteine/pyridoxal
phosphate reduces plasma NO2 =NO

3 , suggesting consumption of
NO possibly through formation of nitosothiol [169,179]. Similarly,
H2S reacts with S-nitrosothiols to form thionitrous acid (HSNO).
These results suggest that, at the cellular level, HSNO can be
metabolized to generate NO+, NO, and NO– species, all of which
have distinct physiological consequences of their own. HSNO also
can freely diffuse through membranes, facilitating trans-nitrosa-
tion of proteins such as hemoglobin. Moreover, HSNO can lead to
the generation of HNO (nitroxyl anion), which has signiﬁcant car-
diopharmacological potential [180]. Likewise, Yong et al. indicate
that H2S interacts with NO to form HNO- that exhibits positive ino-
tropic and lusitropic effects on the heart during inﬂammation-in-
duced arrhythmia [181]. H2S can attenuate isoproterenol induced
cardiac injury and improves survival after cardiac arrest and car-
diopulmonary resuscitation in mice in a NO dependent pathway
[134]. Peroxynitrite rapidly interacts with H2S and generates sulﬁ-
nyl nitrite [HS(O)NO] which abolishes the pro-apoptotic, oxidative
and nitrative properties of peroxynitrite. Furthermore, the thioni-
trate isomer formed is capable of releasing NO in a pH-dependent
manner that likely contributes to the observed cytoprotective ef-
fects [182]. These studies highlight the varied reactions between
NO–H2S and their diverse biochemical products and functions that
are just beginning to be explored.
H2S effects on other reactive oxygen species
H2S may also alter the production of various other reactive oxy-
gen species (ROS). H2S can interfere with NOX driven superoxide
production in vascular smooth muscle cells by inhibiting NOX1
expression and Rac1 activity [183]. Likewise, the effect of perox-
ynitrite can be neutralized by H2S in brain endothelial cells during
oxidative stress and in liver, heart and lung during I/R injury
[7,184], possibly through chemical mechanisms discussed above.
Along this line, it has been suggested that a combination of NO
and H2S therapy may be a better option for treatment of I/R injury
after organ transplantation to effectively balance the impact of
each molecule on ROS toxicity [185]. However, additional studies
are needed to more comprehensively examine the effect of H2S
on ROS formation and associated defense pathways, as it is likely
that both are affected. Future studies should also address if and
how combined H2S/NO based therapeutic approaches are truly
more beneﬁcial for disease states involving redox stress
pathophysiology.Interaction with hemeproteins and non-hemeproteins
Biological compounds containing unpaired electrons such as
sGC, hemoglobin, and cytochrome c oxidase (CcOx) react rapidly
with NO, leading to some of the best-understood physiological ef-
fects of NO [186]. The resulting effect is highly dependent on
their heme protein. For example, reaction of NO with sGC results
in conformational changes in sGC and increases the rate of con-
version of GTP to cGMP by which NO exerts its classical signaling
function. Conversely, sGC is deactivated rapidly after NO removal
[186].
H2S also reacts with hemeproteins in distinct ways: (i) by
incorporation of H2S into one of the pyrrole rings of the heme,
(ii) generating the sulfheme derivative, (iii) binding to alternate
sites of hemeproteins such as cysteine, copper, and zinc ions; or
to the ferric iron with subsequent reduction of the heme, and
(iv) through coordination with the ferric heme iron without induc-
ing reduction or sulfheme production [187]. Likewise, H2S can be
liberated from sulﬁde containing heme-protein by various reduc-
tion processes under different conditions. H2S can also bind to
both Hb and Mb in the ferric state as a heme ligand with lower
afﬁnity, and reduce heme rapidly with the subsequent production
of the deoxy ferrous or oxy ferous-O2 compounds [187,188]. H2S
inhibits cytochrome C activity by directly binding and reducing
its ferric heme a3 and CuB centers, and under moderate concentra-
tion of H2S afﬁnity of heme a3 for O2 decreases, which can stimu-
late muscle relaxation by diminishing cellular ATP formation
[189]. Importantly, NO can react rapidly with metalloproteins
such as iron–sulfur clusters or compounds containing them to
generate dinitrosyl iron complexes [190] that inﬂuence formation
of S-nitrosothiols inside the cells via transnitrosation of NO [191].
Thus, H2S interaction with hemeproteins represents another path-
way whereby H2S and NO chemistry and biology collide although
much less is known about the importance of these reactions under
pathophysiological conditions.NO, XO and H2S interaction
Xanthine oxidase (XO) stimulates biological NO release from S-
nitrosothiols such as S-nitrosocysteine (CysNO) and S-nitrosogluta-
thione (GSNO) under aerobic and anaerobic conditions [192].
Hypoxanthine (HX)/XO interacts with NO to form nitrated uric acid
derivatives that slowly release NO and potentiate the action of NO
for relaxation of the circular muscle of the gastric fundus [193]. Ni-
tric oxide and superoxide anions produced by XO may also lead to
the production of peroxynitrite, which acts as a vasoactive radical
in the fetal-placental vasculature [194]. Nitrite, but not nitrate,
protects against myocardial infarction by a mechanism involving
the xanthine oxidoreductase-signaling pathway [195]. Similarly,
a study showed that under hypoxic conditions, XO reduces nitrate
to nitrite and nitrite to NO at the molybdenum site of the enzyme
in presence of xanthine [196]. These ﬁndings together with work
from our group indicate that H2S can potentiate XO activity facili-
tating nitrite reduction to NO under hypoxic conditions where the
function of NOS is impaired [118,196]. It is known that NO or per-
oxynitrite inhibits XO activity in a dose dependent manner and
attenuates superoxide generation primarily by oxidative disrup-
tion of the molybdenum catalytic site [197]. However, NO inacti-
vated XO activity can be recovered in the presence of a sulﬁde-
generating system under anaerobic conditions suggesting recipro-
cal regulation by NO and sulﬁde on XO activity in the hypoxic state
[198]. Additional studies examining the nature of H2S versus NO
regulation of XO activity are needed and may reveal important
mechanistic insight into how these gasotransmitters work to regu-
late cellular redox balance.
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It is interesting to note that the physiological functions of H2S
are comparable to that of NO, as well as controversy surrounding
their cytoprotective roles. Throughout the literature on H2S it is re-
ported that the cytoprotective and antioxidant effects occur in the
micromolar range; whereas higher H2S exposures, i.e., in the milli-
molar range, potentiate redox stress and are cytotoxic. In the com-
ing future, it is most likely that the ﬁeld will come to realize the
cellular and signalling function and physiological potency of low
nanomolar concentrations of H2S, and that various biochemical
forms of the molecule serve important roles in regulating H2S bio-
availability and cellular redox balance. From the information
above, it is safe to say that H2S serves as a proverbial ‘‘double-
edged sword,’’ where it can be extremely beneﬁcial or harmful
depending on its concentration and cellular location. These obser-
vations also reveal how crucial it is moving forward to accurately
determine and control for the levels of H2S in experimental set-
tings, reinforcing the need for rigorous and reliable measurement
techniques to monitor the biological levels of H2S. Finally, in-
creased clarity regarding sulﬁde cellular signaling will also allevi-
ate confusion and lead to a better understanding of the effects of
H2S administration in biological systems. The future of H2S bio-
chemistry, chemical biology and pathophysiology represent fertile
territory in which to better understand redox processes that will
ultimately be important for human health and disease.
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